INCY - INCYTE CORP

90.3
-1.960   -2.171%

Share volume: 1,488,119
Last Updated: 03-27-2026
Business Services/Services – Research, Development, Testing Labs: -0.05%

PREVIOUS CLOSE
CHG
CHG%
$92.26
-1.96
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 0%
Dept financing 42%
Liquidity 75%
Performance 52%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.17%
1 Month
-9.74%
3 Months
-9.05%
6 Months
7.64%
1 Year
49.01%
2 Year
58.50%
Key data
Stock price
$90.30
P/E Ratio 
15.07
DAY RANGE
$90.20 - $92.50
EPS 
$6.59
52 WEEK RANGE
$53.56 - $112.29
52 WEEK CHANGE
$49.13
MARKET CAP 
19.391 B
YIELD 
N/A
SHARES OUTSTANDING 
199.014 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
BETA 
0.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,758,885
AVERAGE 30 VOLUME 
$1,723,634
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Recent news